i-Stat and Nova Biomedical settle patent suit:
This article was originally published in Clinica
Executive Summary
i-Stat and Nova Biomedical have settled a patent infringement case brought by Nova relating to analysers and cartridges to determine hematocrit. The two companies agreed to dismiss the litigation with prejudice. i-Stat will pay Nova $6.5 million in cash and $3.5 million in a one-year secured promissory note. Nova will grant i-Stat a worldwide, non-exclusive licence to make and sell the devices by any method under the patent. i-Stat will also pay Nova a 4% royalty of the invoice price of products using the licensed method sold in the US from the beginning of this year.
You may also be interested in...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.